Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.56 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3123762 | 0.82 | MEN1 (0.39) | ADORA2AADORA1TNK2MEN1KMT2A | |
| SCHEMBL3124526 | 0.80 | ADORA2A (0.52) | ADORA2AADORA1TNK2MEN1KMT2A | |
| SCHEMBL12728024 | 0.79 | ACHE (0.49) | ADORA2AADORA1ADORA2BADORA3TNK2 | |
| SCHEMBL1644396 | 0.78 | HRH3 (0.44) | ADORA2AADORA1ADORA2BADORA3TNK2 | |
| SCHEMBL1642883 | 0.77 | ADORA2A (0.50) | ADORA2AADORA1ADORA2BADORA3TNK2 | |
| SCHEMBL1643134 | 0.76 | SCN9A (0.43) | ADORA2AADORA1TNK2MEN1KMT2A | |
| SCHEMBL4907342 | 0.75 | ADORA2A (0.56) | ADORA2AADORA1ADORA2BADORA3TNK2 | |
| SCHEMBL1642908 | 0.74 | SCN9A (0.40) | ADORA2AADORA1TNK2MEN1KMT2A | |
| SCHEMBL1643965 | 0.74 | ADORA2A (0.48) | ADORA2AADORA1ADORA2BTNK2MEN1 | |
| SCHEMBL1643667 | 0.74 | TNK2 (0.44) | ADORA2AADORA1TNK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | BAYER HEALTHCARE LLC (US) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098301-A1 | Pyrimidine Derivatives for Treatment of Hyperproliferative Disorders | DPYD, TYMP, TYMS | ADORA2A 1487/4885ADORA1 2071/4885ADORA2B 1614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.